Beijing SL Pharmaceutical Co., Ltd.

Overview

Beijing SL Pharmaceutical Co., Ltd. is a publicly-traded company based in China, engaged in the research, development, and commercialization of pharmaceuticals. The company focuses on developing innovative therapies in various therapeutic areas to improve patient health worldwide.

Therapeutic areas

API / Drug Master Files

Beijing SL Pharmaceutical Co., Ltd. holds 23 active (23 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• LH 3D MSC SFM MEDIUMActive2026-01-29
• MILK EXOSOMESActive2026-01-21
• HUMAN UMBILICAL CORD MESENCHYMAL STEM CELL EXOSOMES (LIQUID)Active2026-01-12
• HUMAN UMBILICAL CORD MESENCHYMAL STEM CELL EXOSOMES (POWDER)Active2026-01-12
• ABEMACICLIBActive2025-12-14
• PROTAMINE SULFATEActive2025-05-28
• GADOTERATE MEGLUMINEActive2024-12-25
• ISAVUCONAZONIUM SULFATEActive2024-10-30
• GADOBUTROLActive2024-09-23
• RELUGOLIXActive2024-09-19
• HUMSC DERIVED EXOSOMESActive2024-08-19
• APALUTAMIDEActive2024-08-13
• LACOSAMIDEActive2024-05-29
• BREXPIPRAZOLEActive2024-01-21
• VORTIOXETINE HYDROBROMIDEActive2023-10-10

Showing 15 of 23 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Beijing SL Pharmaceutical Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.